Promising Treatment Results
Results from a clinical trial showed that alternating the use of "Fotriant" and "Avastin" may help delay disease progression in patients with advanced kidney cancer, providing an additional treatment option for those suffering from this type of cancer. The trial, details of which were reported by Reuters in a report published the day before yesterday, was conducted by researchers from Roswell Park Comprehensive Cancer Center in the United States.
Precise Clinical Data
The trial included 51 patients who had not previously received treatment for advanced kidney cancer. Results showed that the median survival rate was 63.2 months, while the median progression-free survival reached 24.8 months. Researchers tested the drugs "Fotriant" (Pazopanib) and "Avastin" (Bevacizumab) in alternating fashion among patients with metastatic clear cell renal cell carcinoma.
Benefits for Limited Groups
The lead researcher of the study, Dr. Sabi George, from Roswell Park Comprehensive Cancer Center in the United States, explained that results for patients classified in the favorable risk category were similar to or better than some results recorded with modern immunotherapy combinations. He noted that the proposed treatment regimen may be less costly, highlighting its importance for patients who do not suit immunotherapies due to autoimmune diseases, as well as in resource-limited countries.
Warning of Side Effects
Researchers pointed out the necessity of monitoring potential side effects of the treatment, particularly high blood pressure and liver enzymes, emphasizing that initial results need confirmation through broader clinical trials before this regimen is adopted as a standard treatment option. Advanced kidney cancer originates in kidney tissues and then exceeds their boundaries to spread to adjacent or distant tissues and organs, and treatment options vary depending on the stage of the disease and the patient's health status.
Source: Syrian Arab News Agency (SANA)
Comments (0)